secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2025-08-28T23:59:59+00:00
Accession:  0001193125-25-190202
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma receives Paragraph IV notice from Lupin for generic neffy; intends to sue
--------------------------------------------------------------------------------

- Lupin filed ANDA for generic version of neffy (epinephrine nasal spray) before expiration of 8 Orange Book-listed patents.
- Notice alleges patents are invalid, unenforceable, or not infringed; ARS plans to file patent infringement suit within 45 days.
- Filing suit within 45 days triggers automatic 30-month FDA approval stay; company vows to vigorously defend IP.
- As of filing, no other ANDA filers known; neffy is ARS's sole marketed product.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312525190202/0001193125-25-190202-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312525190202/d88536d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-190202

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer